PMID- 11129084
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20221207
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 14
IP  - 5
DP  - 2000 Sep-Oct
TI  - Fluoxetine-induced pressor response in freely moving rats: a role for vasopressin 
      and sympathetic tone.
PG  - 443-51
AB  - The present study was performed in order to assess, in freely moving rats, the 
      cardiovascular effects of central administration of fluoxetine, a serotonin 
      reuptake inhibitor. Two kinds of experiments were performed: 1) acute central 
      administration of fluoxetine. and 2) chronic intraperitoneal administration of 
      fluoxetine plus selegiline, a monoamine oxidase B inhibitor. 
      Intracerebroventricular (i.c.v.) administration of fluoxetine (5-50 microg) 
      induced an increase in blood pressure. This fluoxetine-induced pressor response 
      reached its maximal 1 hour after injection without any significant change in 
      heart rate. At the dose of 10 microg i.c.v., fluoxetine significantly increased 
      mean blood pressure by 16 +/- 4 mmHg. This pressor response was reduced by an 
      intravenous (i.v.) pretreatment with the alpha1-adrenoceptor antagonist, prazosin 
      (500 microg kg(-1)) (+ 7 +/- 4 mmHg, P <0.05) or with the V1A-vasopressin 
      receptor antagonist (20 microg kg(-1)) (+5 +/- 3 mmHg, P < 0.05). The pressor 
      response was completely abolished by a concomitant pretreatment with prazosin 
      plus the V1A-vasopressin receptor antagonist. Pretreatment with the 
      beta-adrenoceptor antagonist, propranolol (1 mg kg(-1) i.v.), or the 5-HT2 
      receptor antagonist, ketanserine (5 mg kg(-1) i.v.), did not modify the 
      fluoxetine-induced pressor response. In freely moving rats receiving fluoxetine 
      (10 microg i.c.v.), vasopressin plasma levels were significantly higher (39 +/- 5 
      pg mL(-1) than in rats receiving 10 microL i.c.v. saline (14 +/- 4 pg mL(-1)). A 
      30 day intraperitoneal (i.p.) administration of fluoxetine in association with 
      selegiline induced an increase in noradrenaline plasma levels and locomotor 
      activity without any significant change in blood pressure and heart rate. These 
      data suggest that, the pressor response elicited by central acute administration 
      of fluoxetine is mediated by both an increase in sympathetic tone and vasopressin 
      release. This observation could suggest the putative interest of 
      alpha1-adrenoceptor and or V1A-vasopressin receptor antagonists in the treatment 
      of "Serotonin Syndrome".
FAU - Lazartigues, E
AU  - Lazartigues E
AD  - Laboratoire de Pharmacologie Medicale et Clinique, Inserm U317 and Centre 
      Midi-Pyrenees de Pharmacovigilance, de Pharmacoepidemiologie et d'Informations 
      sur le Medicament, Faculte de Medecine, Toulouse, France.
FAU - Brefel-Courbon, C
AU  - Brefel-Courbon C
FAU - Bagheri, H
AU  - Bagheri H
FAU - Costes, S
AU  - Costes S
FAU - Gharib, C
AU  - Gharib C
FAU - Tran, M A
AU  - Tran MA
FAU - Senard, J M
AU  - Senard JM
FAU - Montastruc, J L
AU  - Montastruc JL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 11000-17-2 (Vasopressins)
RN  - 2K1V7GP655 (Selegiline)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Drug Interactions
MH  - Fluoxetine/administration & dosage/*pharmacology
MH  - Neuroprotective Agents/pharmacology
MH  - Pressoreceptors/*drug effects/physiology
MH  - Rats
MH  - Rats, Wistar
MH  - Selegiline/pharmacology
MH  - Selective Serotonin Reuptake Inhibitors/administration & dosage/*pharmacology
MH  - Sympathetic Nervous System/*drug effects/physiology
MH  - Vasopressins/*physiology
EDAT- 2000/12/29 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/12/29 11:00
PHST- 2000/12/29 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/12/29 11:00 [entrez]
AID - S076739810001080X [pii]
AID - 10.1111/j.1472-8206.2000.tb00426.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2000 Sep-Oct;14(5):443-51. doi: 
      10.1111/j.1472-8206.2000.tb00426.x.